Ensysce Biosciences, Inc.

ENSCNASDAQHealthcare● Active

$0.25

$-0.00(-0.43%)

Market Cap$2347288

P/E Ratio—

52W High$2.75

52W Low$0.23

Avg Volume2.2M

Open$0.26

Beta0.84

Free Cash Flow Financials Revenue

Ensysce Biosciences, Inc. (ENSC) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ENSC · free cash flow · updated Jun 8, 2026

Core FCF metrics

ENSC · FCF · TTM · margin & CAGR

Free cash flow was −$7.81T for FY2025 (fiscal year ending 2025-12-31), down 4.0% year-over-year

FY2025 Free Cash Flow−$7.81T▼ -4.0% YoY

Trailing 12M (TTM)−$9.7Mtrailing 4 quarters sum

FCF Margin< −999%−$7.81T ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ENSC · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$7.81T(0M)−$7.81T▼ 4.0%—

FY2024−$7.50T(0M)−$7.50T▼ 69598346.5%—

FY2023−$10.8M(0M)−$10.8M▲ +39.7%-483.2%

FY2022−$17.9M(0M)−$17.9M▼ 117.0%-708.9%

FY2021−$8.2M(0M)−$8.2M▼ 560.8%-233.4%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ENSC · P/FCF · FCF yield · FCF per share

Ensysce Biosciences, Inc. (ENSC) reported negative free cash flow of −$7806.29B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ENSC · cash flow statement · operating / investing / financing

For FY2025, Ensysce Biosciences, Inc. generated −$7.81T in operating cash flow and spent 0M in capital expenditures, yielding −$7.81T in free cash flow.

Operating Activities

−$7.81T

Cash from core business operations

2025-12-31

Investing Activities

−$123.64B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$8.74T

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$7.81T) − |CapEx| (0M) = FCF (−$7.81T)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ENSC vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Ensysce Biosciences, Inc.YOU

ENSC

−$7.81T-4.0%-154072059.4%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Ensysce Biosciences, Inc. (ENSC) reported free cash flow of −$7.81T for FY2025 (fiscal year ending 2025-12-31), down 4.0% year-over-year.

Based on available data, Ensysce Biosciences, Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $11.0M in FY2019.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ENSC free cash flow · 8 questions

Ensysce Biosciences, Inc. free cash flow was −$7.81T for FY2025, down 4.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$9.7M.

ENSC free cash flowENSC FCFENSC FCF 2025ENSC free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Ensysce Biosciences, Inc. · Ensysce Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026